Therapeutic strategies promoting NK8+ differentiation or altered T cell HLA-G expression may have coordinated regulatory effects on pathogenic T cells to limit demyelination in CIS/RRMS. The gene discussed is HLA-G; the disease is relapsing-remitting multiple sclerosis.